These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14755983)

  • 1. [Secondary effects of chronic treatment with levodopa in Parkinson disease].
    Baltag D; Ignat B; Manole OZ
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):131-5. PubMed ID: 14755983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 4. [Motor complications of treatment with levodopa in Parkinson's disease].
    García-Escrig M; Bermejo-Pareja F
    Rev Neurol; 1999 Apr 16-30; 28(8):799-809. PubMed ID: 10363326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
    Nakamura Y; Yoshinaga J; Endo S; Hikiji A
    Rinsho Shinkeigaku; 1997 Jun; 37(6):469-75. PubMed ID: 9366172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
    Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
    Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Pouclet H; Derkinderen P; Lebouvier T
    Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Molchadski I; Korczyn AD; Cohen OS; Katzav A; Nitzan Z; Chapman J; Hassin-Baer S
    Acta Neurol Scand; 2011 Feb; 123(2):117-21. PubMed ID: 21108621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 11. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.
    Prashantha DK; Pal PK
    Parkinsonism Relat Disord; 2009 Nov; 15(9):718-9. PubMed ID: 19157953
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
    Fabbrini G; Defazio G; Colosimo C; Suppa A; Bloise M; Berardelli A
    Mov Disord; 2009 Oct; 24(14):2091-6. PubMed ID: 19691126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
    García-Escrig M; Bermejo Pareja F; Fernández Ponsatí JT
    Med Clin (Barc); 1999 Feb; 112(7):245-50. PubMed ID: 10220750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 19. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

  • 20. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.